CARLSBAD, Calif., Aug. 30 /PRNewswire-FirstCall/ — Isis
Pharmaceuticals, Inc. (Nasdaq:
ISIS) announces the following webcast:What:
Data from mipomersen Phase 3 trial in heFH patients presented at
Wednesday, September 1, 2010 at 4:00 p.m. ET / 1:00 p.m.
Live on the Internet. Simply log onto our Web site listed
above. If you are unable to participate during the live event, a
replay of the webcast will be available for a limited time at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its
expertise in RNA to discover and develop novel drugs for its
product pipeline and for its partners. The Company has
successfully commercialized the world’s first antisense drug and
has 23 drugs in development. Isis’ drug development programs
are focused on treating cardiovascular, metabolic, and severe
neurodegenerative diseases and cancer. Isis’ partners are
developing antisense drugs invented by Isis to treat a wide variety
of diseases. Isis and Alnylam Pharmaceuticals are joint
owners of Regulus Therapeutics Inc., a company focused on the
discovery, development and commercialization of microRNA
therapeutics. Isis also has made significant innovations
beyond human therapeutics resulting in products that other
companies, including Abbott, are commercializing. As an
innovator in RNA-based drug discovery and development, Isis is the
owner or exclusive licensee of over 1,600 issued patents worldwide.
Additional information about Isis is available at www.isispharm.com.